StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research note released on Saturday. The firm issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Up 5.1 %
NASDAQ:XXII opened at $0.11 on Friday. The stock’s 50 day moving average price is $0.27 and its 200 day moving average price is $0.78. The company has a market capitalization of $932,850.00, a PE ratio of 0.00 and a beta of 1.39. 22nd Century Group has a 52-week low of $0.09 and a 52-week high of $8.63.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%. The firm had revenue of $7.95 million for the quarter.
Institutional Inflows and Outflows
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- Canadian Penny Stocks: Can They Make You Rich?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 Fintech Stocks With Good 2021 Prospects
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Read Stock Charts for Beginners
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.